FI114154B - Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi Download PDF

Info

Publication number: FI114154B
Authority: FI; Finland
Prior art keywords: magnesium; process according; omeprazole; crystalline; isomeprazole
Prior art date: 1993-07-09

Application number

FI960101A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI960101A0 (fi

FI960101L (fi

Inventor

Lars Aake Kaellstroem

Monica Annelie Nygren

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-09

Filing date

1996-01-09

Publication date

2004-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI114154(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-01-09 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

1996-01-09 Publication of FI960101A0 publication Critical patent/FI960101A0/fi

1996-01-09 Publication of FI960101L publication Critical patent/FI960101L/fi

2004-08-31 Application granted granted Critical

2004-08-31 Publication of FI114154B publication Critical patent/FI114154B/fi

Links

238000000034 method Methods 0.000 title claims abstract description 35
KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 title claims abstract description 29
238000002360 preparation method Methods 0.000 title claims description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 17
229960000381 omeprazole Drugs 0.000 claims description 17
239000011777 magnesium Substances 0.000 claims description 16
229910052749 magnesium Inorganic materials 0.000 claims description 15
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
238000002425 crystallisation Methods 0.000 claims description 7
230000008025 crystallization Effects 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 5
238000005119 centrifugation Methods 0.000 claims description 4
238000001914 filtration Methods 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 3
238000004817 gas chromatography Methods 0.000 claims description 3
239000002798 polar solvent Substances 0.000 claims description 3
238000001704 evaporation Methods 0.000 claims 1
238000010438 heat treatment Methods 0.000 claims 1
230000036651 mood Effects 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 claims 1
239000011541 reaction mixture Substances 0.000 claims 1
239000013557 residual solvent Substances 0.000 claims 1
238000004448 titration Methods 0.000 claims 1
238000005406 washing Methods 0.000 claims 1
230000004584 weight gain Effects 0.000 claims 1
235000019786 weight gain Nutrition 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 8
150000001875 compounds Chemical group 0.000 abstract description 3
238000000634 powder X-ray diffraction Methods 0.000 abstract description 3
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000047 product Substances 0.000 description 14
239000013078 crystal Substances 0.000 description 7
159000000003 magnesium salts Chemical class 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000002245 particle Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
241000189662 Calla Species 0.000 description 1
206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229910003480 inorganic solid Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Contacts (AREA)
Electroplating Methods And Accessories (AREA)
Conductive Materials (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Fats And Perfumes (AREA)
Medicinal Preparation (AREA)
Glass Compositions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Powder Metallurgy (AREA)

FI960101A 1993-07-09 1996-01-09 Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi FI114154B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE9302396		1993-07-09
SE19939302396A SE9302396D0 (sv)	1993-07-09	1993-07-09	A novel compound form
PCT/SE1994/000680 WO1995001977A1 (fr)	1993-07-09	1994-07-08	Omeprazole de magnesium
SE9400680		1994-07-08

Publications (3)

Publication Number	Publication Date
FI960101A0 FI960101A0 (fi)	1996-01-09
FI960101L FI960101L (fi)	1996-01-09
FI114154B true FI114154B (fi)	2004-08-31

Family

ID=20390588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI960101A FI114154B (fi)	1993-07-09	1996-01-09	Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi

Country Status (41)

Country	Link
US (1)	US5900424A (fr)
EP (2)	EP0707580B1 (fr)
JP (2)	JP3635432B2 (fr)
KR (1)	KR100353783B1 (fr)
CN (1)	CN1064680C (fr)
AT (1)	ATE212628T1 (fr)
AU (1)	AU679766B2 (fr)
BR (1)	BR9406940A (fr)
CA (1)	CA2166794C (fr)
CZ (1)	CZ288933B6 (fr)
DE (2)	DE69429774T2 (fr)
DK (1)	DK0707580T3 (fr)
DZ (1)	DZ1792A1 (fr)
EE (1)	EE03127B1 (fr)
EG (1)	EG21437A (fr)
ES (1)	ES2100136T3 (fr)
FI (1)	FI114154B (fr)
GR (1)	GR970300015T1 (fr)
HR (1)	HRP940385B1 (fr)
HU (1)	HU226861B1 (fr)
IL (1)	IL110190A (fr)
IS (1)	IS2075B (fr)
MA (1)	MA23257A1 (fr)
MX (1)	MX9405217A (fr)
MY (1)	MY113274A (fr)
NO (1)	NO308702B1 (fr)
NZ (1)	NZ268693A (fr)
PL (1)	PL175999B1 (fr)
PT (1)	PT707580E (fr)
RU (1)	RU2139868C1 (fr)
SA (1)	SA94150058B1 (fr)
SE (1)	SE9302396D0 (fr)
SG (1)	SG52464A1 (fr)
SI (1)	SI0707580T1 (fr)
SK (1)	SK281230B6 (fr)
TN (1)	TNSN94079A1 (fr)
TW (1)	TW504509B (fr)
UA (1)	UA43343C2 (fr)
WO (1)	WO1995001977A1 (fr)
YU (1)	YU49193B (fr)
ZA (1)	ZA944933B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875872B1 (en)	1993-05-28	2005-04-05	Astrazeneca	Compounds
SE9301830D0 (sv) *	1993-05-28	1993-05-28	Ab Astra	New compounds
SE9302395D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	New pharmaceutical formulation
SE9302396D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	A novel compound form
SI0723436T1 (en)	1994-07-08	2002-02-28	Astrazeneca Ab	Multiple unit tableted dosage form i
CA2193681A1 (fr) *	1994-07-08	1996-01-25	Astra Aktiebolag	Nouvelle preparation pharmaceutique a administration orale contenant un sel magnesien d'omeprazole
SE9500478D0 (sv) *	1995-02-09	1995-02-09	Astra Ab	New pharmaceutical formulation and process
US6645988B2 (en)	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) *	1996-01-04	2004-03-02	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and methods of using same
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv)	1996-01-08	1996-01-08	Astra Ab	New oral pharmaceutical dosage forms
SE508669C2 (sv) *	1996-04-26	1998-10-26	Astra Ab	Nytt förfarande
US6623759B2 (en)	1996-06-28	2003-09-23	Astrazeneca Ab	Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) *	1996-11-14	2000-03-21	Takeda Chemical Industries Ltd	Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) *	1996-12-20	1999-06-14	Astra Ab	Nya Kristallmodifikationer
SE9702000D0 (sv) *	1997-05-28	1997-05-28	Astra Ab	New pharmaceutical formulation
US6747155B2 (en)	1997-05-30	2004-06-08	Astrazeneca Ab	Process
SE510650C2 (sv)	1997-05-30	1999-06-14	Astra Ab	Ny förening
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
SE9704870D0 (sv)	1997-12-22	1997-12-22	Astra Ab	New pharmaceutical formulation I
FR2774288B1 (fr) *	1998-01-30	2001-09-07	Ethypharm Sa	Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) *	1998-04-22	2000-04-11	Torcan Chemical Ltd.	Magnesium omeprazole and process for its preparation
DE19843413C1 (de)	1998-08-18	2000-03-30	Byk Gulden Lomberg Chem Fab	Neue Salzform von Pantoprazol
US6733778B1 (en)	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
SE9803772D0 (sv)	1998-11-05	1998-11-05	Astra Ab	Pharmaceutical formulation
UA72748C2 (en) *	1998-11-10	2005-04-15	Astrazeneca Ab	A novel crystalline form of omeprazole
IL142703A (en) *	1998-11-10	2006-04-10	Astrazeneca Ab	Crystalline form of omeprazole
BR9915421A (pt) *	1998-11-18	2001-08-07	Astrazeneca Ab	Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica.
TWI243672B (en)	1999-06-01	2005-11-21	Astrazeneca Ab	New use of compounds as antibacterial agents
US6316020B1 (en) *	1999-08-26	2001-11-13	Robert R. Whittle	Pharmaceutical formulations
SE9903831D0 (sv) *	1999-10-22	1999-10-22	Astra Ab	Formulation of substituted benzimidazoles
CA2290893C (fr) *	1999-11-16	2007-05-01	Bernard Charles Sherman	Omeprazole de magnesium
DE19959419A1 (de) *	1999-12-09	2001-06-21	Ratiopharm Gmbh	Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
SE0000774D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	New formulation
US20030212274A1 (en) *	2000-05-15	2003-11-13	Bakthavathsalan Vijayaraghavan	Novel amorphous form of omeprazole salts
AU2001276721A1 (en)	2000-08-04	2002-02-18	Takeda Chemical Industries Ltd.	Salts of benzimidazole compound and use thereof
CA2386716C (fr) *	2002-05-17	2012-07-24	Bernard Charles Sherman	Sel de magnesium de s-omeprazole
US6544556B1 (en)	2000-09-11	2003-04-08	Andrx Corporation	Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) *	2000-09-29	2002-04-08	Geneva Pharmaceuticals, Inc.	Proton pump inhibitor formulation
SE0101379D0 (sv)	2001-04-18	2001-04-18	Diabact Ab	Komposition som hämmar utsöndring av magsyra
US8206741B2 (en)	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv)	2001-09-07	2001-09-07	Astrazeneca Ab	New self emulsifying drug delivery system
WO2003063840A2 (fr) *	2002-01-25	2003-08-07	Santarus, Inc.	Administration par voie muqueuse d'inhibiteurs de la pompe a protons
FR2836228B1 (fr) *	2002-02-21	2005-08-19	Inst Francais Du Petrole	Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) *	2002-06-07	2003-12-11	Patel Mahendra R.	Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv)	2002-10-16	2002-10-16	Diabact Ab	Gastric acid secretion inhibiting composition
EP1603537A4 (fr) *	2003-02-20	2009-11-04	Santarus Inc	Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique
WO2004099181A1 (fr) *	2003-05-05	2004-11-18	Ranbaxy Laboratories Limited	Sel de baryum d'un derive de benzimidazole
US8993599B2 (en) *	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045062A1 (es) *	2003-07-18	2005-10-12	Santarus Inc	Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
TWI337877B (en) *	2003-07-18	2011-03-01	Santarus Inc	Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
EP2184058B1 (fr)	2003-09-26	2012-02-08	ALZA Corporation	Enrobage de médicaments à charge médicamenteuse élevée et procès de fabrication
RU2257890C2 (ru) *	2003-10-06	2005-08-10	Марио Атилио Лос	Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
WO2005082888A1 (fr) *	2004-03-01	2005-09-09	Milen Merkez Ilac Endustrisi A.S.	Procede de preparation d'un sel magnesique d'omeprazole
US8906940B2 (en) *	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) *	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) *	2004-07-02	2007-06-01	Esteve Quimica, S.A.	Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) *	2004-07-29	2006-02-02	Pawan Seth	Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en)	2004-09-24	2013-09-24	Abbvie Inc.	Sustained release formulations of opioid and nonopioid analgesics
WO2006067599A2 (fr)	2004-12-23	2006-06-29	Ranbaxy Laboratories Limited	Compositions orales stables de benzimidazoles et leur procede de preparation
US20060160783A1 (en) *	2004-12-30	2006-07-20	Transform Pharmaceuticals, Inc.	Novel omeprazole forms and related methods
WO2006087613A2 (fr) *	2005-02-02	2006-08-24	Ranbaxy Laboratories Limited	Compositions de benzimidazole orales stables preparees par un procede de stratification non aqueux
US7981908B2 (en)	2005-05-11	2011-07-19	Vecta, Ltd.	Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en)	2005-05-11	2010-09-28	Vecta, Ltd.	Composition and methods for inhibiting gastric acid secretion
CA2624179A1 (fr) *	2005-10-06	2007-04-12	Auspex Pharmaceuticals, Inc.	Inhibiteurs deuteries d'atpase h+,k+ gastrique ayant des proprietes therapeutiques renforcees
EP1801110A1 (fr)	2005-12-22	2007-06-27	KRKA, tovarna zdravil, d.d., Novo mesto	Sel d'arginine d'ésoméprazole
US7553857B2 (en)	2005-12-23	2009-06-30	Lek Pharmaceuticals D.D.	S-omeprazole magnesium
AU2007266574A1 (en) *	2006-06-01	2007-12-06	Dexcel Pharma Technologies Ltd.	Multiple unit pharmaceutical formulation
ES2511792T3 (es)	2006-07-25	2014-10-23	Vecta Ltd.	Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
GB2444593B (en)	2006-10-05	2010-06-09	Santarus Inc	Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) *	2007-10-05	2009-04-09	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es)	2006-10-27	2009-08-12	Univ Missouri	Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EP1947099A1 (fr)	2007-01-18	2008-07-23	LEK Pharmaceuticals D.D.	Procédé pour l'élimination de solvant des sels d'oméprazole
US8911787B2 (en)	2008-02-26	2014-12-16	Ranbaxy Laboratories Limited	Stable oral benzimidazole compositions and process of preparation thereof
JP5302389B2 (ja)	2008-04-29	2013-10-02	エフ．ホフマン−ラロシュアーゲー	Ｊｎｋのピリミジニルピリドンインヒビター
US20090280173A1 (en) *	2008-05-09	2009-11-12	Ishwar Chauhan	Multilayer Omeprazole Tablets
US20090280175A1 (en) *	2008-05-09	2009-11-12	Ishwar Chauhan	Multilayer Proton Pump Inhibitor Tablets
EP2147918A1 (fr)	2008-07-21	2010-01-27	LEK Pharmaceuticals D.D.	Procédé de préparation de magnésium d'oméprazole S dans une forme stable
BRPI0918492A2 (pt)	2008-09-09	2015-12-01	Astrazeneca Ab	uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
WO2010122583A2 (fr)	2009-04-24	2010-10-28	Rubicon Research Private Limited	Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
EP2445499A4 (fr)	2009-06-25	2013-02-27	Astrazeneca Ab	Procede pour le traitement d'un patient a risque de developer un ulcere associe a nsaid
EA021112B1 (ru) *	2009-06-25	2015-04-30	Поузен Инк.	Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
WO2011080502A2 (fr)	2009-12-29	2011-07-07	Orexo Ab	Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
US20120294937A1 (en)	2009-12-29	2012-11-22	Novartis Ag	New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (fr)	2009-12-29	2011-07-07	Orexo Ab	Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2345408A3 (fr)	2010-01-08	2012-02-29	Dr. Reddy's Laboratories Ltd.	Formulations de médicament labiles acides
EP2601947A1 (fr)	2011-12-05	2013-06-12	Abo Bakr Mohammed Ali Al-Mehdar	Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
CA2860231A1 (fr)	2011-12-28	2013-07-04	Pozen Inc.	Compositions et procedes d'administration d'omeprazole plus acide acetylsalicylique ameliores
CN102993184A (zh) *	2013-01-08	2013-03-27	湖南方盛制药股份有限公司	一种埃索美拉唑及其镁盐三水合物的制备方法
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10736855B2 (en)	2016-02-25	2020-08-11	Dexcel Pharma Technologies Ltd.	Compositions comprising proton pump inhibitors
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
JP2025532389A (ja)	2022-10-04	2025-09-29	ザビリュク，アルセニー	大動脈弁の石灰化の抑制

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
SE8301182D0 (sv) *	1983-03-04	1983-03-04	Haessle Ab	Novel compounds
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
DE4035455A1 (de) *	1990-11-08	1992-05-14	Byk Gulden Lomberg Chem Fab	Enantiomerentrennung
SE9302396D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	A novel compound form

1993
- 1993-07-09 SE SE19939302396A patent/SE9302396D0/xx unknown
1994
- 1994-06-23 TW TW083105710A patent/TW504509B/zh not_active IP Right Cessation
- 1994-07-01 HR HR940385A patent/HRP940385B1/xx not_active IP Right Cessation
- 1994-07-01 IL IL11019094A patent/IL110190A/xx not_active IP Right Cessation
- 1994-07-04 SA SA94150058A patent/SA94150058B1/ar unknown
- 1994-07-05 IS IS4186A patent/IS2075B/is unknown
- 1994-07-07 ZA ZA944933A patent/ZA944933B/xx unknown
- 1994-07-07 MA MA23567A patent/MA23257A1/fr unknown
- 1994-07-07 EG EG40794A patent/EG21437A/xx active
- 1994-07-07 MY MYPI94001774A patent/MY113274A/en unknown
- 1994-07-08 DE DE69429774T patent/DE69429774T2/de not_active Expired - Lifetime
- 1994-07-08 UA UA96010059A patent/UA43343C2/uk unknown
- 1994-07-08 US US08/313,342 patent/US5900424A/en not_active Expired - Lifetime
- 1994-07-08 SI SI9430414T patent/SI0707580T1/xx unknown
- 1994-07-08 DK DK94921154T patent/DK0707580T3/da active
- 1994-07-08 SK SK22-96A patent/SK281230B6/sk not_active IP Right Cessation
- 1994-07-08 MX MX9405217A patent/MX9405217A/es unknown
- 1994-07-08 RU RU96102079A patent/RU2139868C1/ru active
- 1994-07-08 DE DE0707580T patent/DE707580T1/de active Pending
- 1994-07-08 YU YU43694A patent/YU49193B/sh unknown
- 1994-07-08 ES ES94921154T patent/ES2100136T3/es not_active Expired - Lifetime
- 1994-07-08 TN TNTNSN94079A patent/TNSN94079A1/fr unknown
- 1994-07-08 SG SG1996004887A patent/SG52464A1/en unknown
- 1994-07-08 HU HU9503873A patent/HU226861B1/hu unknown
- 1994-07-08 EP EP94921154A patent/EP0707580B1/fr not_active Expired - Lifetime
- 1994-07-08 AT AT94921154T patent/ATE212628T1/de active
- 1994-07-08 AU AU71981/94A patent/AU679766B2/en not_active Expired
- 1994-07-08 WO PCT/SE1994/000680 patent/WO1995001977A1/fr not_active Ceased
- 1994-07-08 BR BR9406940A patent/BR9406940A/pt not_active Application Discontinuation
- 1994-07-08 CZ CZ199669A patent/CZ288933B6/cs not_active IP Right Cessation
- 1994-07-08 PL PL94312440A patent/PL175999B1/pl unknown
- 1994-07-08 NZ NZ268693A patent/NZ268693A/en not_active IP Right Cessation
- 1994-07-08 JP JP50400595A patent/JP3635432B2/ja not_active Expired - Lifetime
- 1994-07-08 CN CN94192733A patent/CN1064680C/zh not_active Expired - Lifetime
- 1994-07-08 PT PT94921154T patent/PT707580E/pt unknown
- 1994-07-08 CA CA002166794A patent/CA2166794C/fr not_active Expired - Lifetime
- 1994-07-08 KR KR1019960700051A patent/KR100353783B1/ko not_active Expired - Lifetime
- 1994-07-08 EP EP01117362A patent/EP1164132A3/fr not_active Withdrawn
- 1994-11-17 EE EE9400405A patent/EE03127B1/xx unknown
- 1994-11-27 DZ DZ940071A patent/DZ1792A1/fr active
1996
- 1996-01-05 NO NO960068A patent/NO308702B1/no not_active IP Right Cessation
- 1996-01-09 FI FI960101A patent/FI114154B/fi not_active IP Right Cessation
1997
- 1997-05-30 GR GR970300015T patent/GR970300015T1/el unknown
2001
- 2001-09-26 JP JP2001293480A patent/JP3878826B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
YU49193B (sh)	2004-09-03
AU7198194A (en)	1995-02-06
DE69429774T2 (de)	2002-11-14
KR100353783B1 (ko)	2004-04-03
US5900424A (en)	1999-05-04
CN1064680C (zh)	2001-04-18
PL312440A1 (en)	1996-04-29
YU43694A (sh)	1997-07-31
ES2100136T1 (es)	1997-06-16
BR9406940A (pt)	1996-09-10
HRP940385A2 (en)	1997-02-28
MY113274A (en)	2002-01-31
SK2296A3 (en)	1996-10-02
SK281230B6 (sk)	2001-01-18
MA23257A1 (fr)	1995-04-01
IL110190A (en)	2000-07-26
WO1995001977A1 (fr)	1995-01-19
EP0707580A1 (fr)	1996-04-24
FI960101A0 (fi)	1996-01-09
RU2139868C1 (ru)	1999-10-20
EP1164132A2 (fr)	2001-12-19
HK1008329A1 (en)	1999-05-07
CZ6996A3 (en)	1996-05-15
NO960068L (no)	1996-01-05
AU679766B2 (en)	1997-07-10
NZ268693A (en)	1997-05-26
ZA944933B (en)	1995-02-20
JP3878826B2 (ja)	2007-02-07
CN1126993A (zh)	1996-07-17
ES2100136T3 (es)	2002-09-01
EP1164132A3 (fr)	2002-01-02
DK0707580T3 (da)	2002-04-15
EG21437A (en)	2001-10-31
MX9405217A (es)	1995-01-31
ATE212628T1 (de)	2002-02-15
GR970300015T1 (en)	1997-05-31
HRP940385B1 (en)	2003-06-30
DZ1792A1 (fr)	2002-02-17
SE9302396D0 (sv)	1993-07-09
EE03127B1 (et)	1998-10-15
CA2166794C (fr)	1997-03-04
NO960068D0 (no)	1996-01-05
HU9503873D0 (en)	1996-02-28
JP3635432B2 (ja)	2005-04-06
UA43343C2 (uk)	2001-12-17
HU226861B1 (en)	2009-12-28
DE69429774D1 (de)	2002-03-14
IL110190A0 (en)	1994-10-21
JPH08512315A (ja)	1996-12-24
JP2002105072A (ja)	2002-04-10
NO308702B1 (no)	2000-10-16
PT707580E (pt)	2002-06-28
EP0707580B1 (fr)	2002-01-30
DE707580T1 (de)	1997-09-04
TNSN94079A1 (fr)	1995-04-25
PL175999B1 (pl)	1999-03-31
HUT75314A (en)	1997-05-28
CZ288933B6 (cs)	2001-09-12
IS2075B (is)	2005-12-15
IS4186A (is)	1995-01-10
SA94150058B1 (ar)	2006-06-20
FI960101L (fi)	1996-01-09
SI0707580T1 (en)	2002-06-30
TW504509B (en)	2002-10-01
SG52464A1 (en)	1998-09-28

Publication	Publication Date	Title
FI114154B (fi)	2004-08-31	Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi
WO1995001977A9 (fr)	1996-02-01	Omeprazole de magnesium
RS49597B (sr)	2007-06-04	Olanzapin dihidrat d
ME00198B (me)	2011-02-10	Novi oblik s-omeprazola
RU2385325C2 (ru)	2010-03-27	Способ получения сульфата атазанавира
KR20030042038A (ko)	2003-05-27	온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법
WO2000078729A1 (fr)	2000-12-28	Formes cristallines du lansoprazole
US4668674A (en)	1987-05-26	(+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11H-dibenzo[b,][1,4]diazepin-11-one, the isolation thereof and its use as a pharmaceutical material
JPH06192228A (ja)	1994-07-12	結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
HK1008329B (en)	2002-05-17	Magnesium omeprazole
CH644375A5 (fr)	1984-07-31	Pyridylaminotriazoles et composition pharmaceutique les contenant.
EP0340030A2 (fr)	1989-11-02	Dérivés de triazine
JPH0359063B2 (fr)	1991-09-09
JPH08239381A (ja)	1996-09-17	安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
FR2523972A1 (fr)	1983-09-30	Derives vinyliques substitues de la 1h-pyrazolo-(1,5-a) pyrimidine utiles notamment comme medicaments antiulcerigenes et antisecretoires gastriques et procede de leur preparation
TW200827357A (en)	2008-07-01	Improved process for the manufacture of mirtazapine
FI88039C (fi)	1993-03-25	Foerfarande foer framstaellning av 2,3-dihydro-1-(8-metyl-1,2,4-triatsolo/4,3-b/pyridazin-6-yl)-4(1h)-pyridinon
MXPA01004794A (en)	2008-10-03	Crystalline forms of 3-(2, 4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
JP2003137889A (ja)	2003-05-14	チエノピリジン誘導体の製造法
HK1024687B (en)	2004-01-16	Polymorphs of 8-chloro-6, 11-dihydro-11-(4-piperidylidene) -5h-benzo[5,6] cyclohepta[1,2-b]pyridine

Legal Events

Date	Code	Title	Description
2014-08-28	MA	Patent expired